(RTTNews) - Biopharmaceutical company Werewolf Therapeutics, Inc. (HOWL) announced Wednesday that it has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc. (MRK), known as MSD outside the U.S. and Canada, to evaluate WTX-124, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy.
WTX-124 is a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE product candidate that has been engineered to minimize the severe toxicities that have been observed with recombinant IL-2 therapy.
The planned clinical trial will be conducted by Werewolf Therapeutics and is designed to evaluate the safety and preliminary efficacy of WTX-124 as a monotherapy and in combination with KEYTRUDA in patients with solid tumors.
Werewolf Therapeutics plans to submit an investigational new drug (IND) application for WTX-124 to the U.S. Food and Drug Administration (FDA) in the first half of 2022.
Subject to FDA clearance of the IND application, Werewolf Therapeutics expects to promptly initiate a Phase 1 clinical trial evaluating WTX-124 as a monotherapy and as a combination therapy with KEYTRUDA for the treatment of solid tumors.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
